Equillium Inc. (NASDAQ: EQ) Stock Information | RedChip

Equillium Inc. (NASDAQ: EQ)


$0.5930
-0.0528 ( -1.17% ) 108.7K

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Market Data


Open


$0.5930

Previous close


$0.6458

Volume


108.7K

Market cap


$22.88M

Day range


$0.5790 - $0.6480

52 week range


$0.5605 - $3.2500

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Oct 29, 2024
4 Insider transactions 1 Sep 27, 2024
4 Insider transactions 1 Sep 17, 2024
10-q Quarterly Reports 60 Aug 08, 2024
8-k 8K-related 14 Aug 08, 2024
8-k 8K-related 13 Jul 23, 2024
4 Insider transactions 1 Jul 18, 2024
8-k 8K-related 13 Jul 18, 2024
8-k 8K-related 45 Jun 04, 2024
4 Insider transactions 1 May 23, 2024

Latest News